ClinicalTrials.gg
Status unknownNCT04180982Updated Dec 2, 2019

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

A Phase 2 interventional study of SHR4640 dose1 plus Febuxostat dose1 and SHR4640 dose1 plus Febuxostat dose2 in Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-02.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hyperuricemia by Jiangsu HengRui Medicine Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Hyperuricemia · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
7th of 15
84 · median 50
Started
2019
with 1 other
Phase 2
4 of 15
1 open now
Registered
6th of 15
by date

Among the 15 studies in Hyperuricemia by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 2 that started in 2019, is one of 4 in phase 2, and was the 6th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 15 studies in Hyperuricemia by Jiangsu HengRui Medicine Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hyperuricemia by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.

03

Conditions studied

  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a ≥18 and ≤30 kg/m2;
  • Screening sUA value ≥8mg/dl;
  • Subject has no abnormalities in vital signs, , physical examination,imaging examination or safety laboratory values.

Exclusion criteria

Exclusion Criteria:

  • Subject known or suspected of being sensitive to the study drugs or its ingredient;
  • 、AST、>1.5ULN;
  • History of kidney stones or screening kidney stones by B-ultrasound;
  • History of ;
  • History of xanthinuria;
  • Donated blood(≥400ml)within 3 months prior to screening or received transfusion of blood.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    SHR4640 dose1 Oral Tablet plus Febuxostat dose1 Oral Tablet Day1\~Day28 qd.

    Drug: SHR4640 dose1 plus Febuxostat dose1

  • Experimental
    Treatment group B

    SHR4640 dose1 Oral Tablet plus Febuxostat dose2 Oral Tablet Day1\~Day28 qd.

    Drug: SHR4640 dose1 plus Febuxostat dose2

  • Experimental
    Treatment group C

    SHR4640 dose2 Oral Tablet plus Febuxostat dose3 Oral Tablet Day1\~Day28 qd.

    Drug: SHR4640 dose2 plus Febuxostat dose3

Interventions

  • DrugSHR4640 dose1 plus Febuxostat dose1

    Tablet,dose1,QD

  • DrugSHR4640 dose1 plus Febuxostat dose2

    Tablet,dose1, dose2 QD

  • DrugSHR4640 dose2 plus Febuxostat dose3

    Tablet,dose2, dose3 QD

06

What researchers measure

Primary outcomes

  1. Adverse Events(AEs) and Serious Adverse Events(SAEs)

    Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events, incidence of drug related adverse events (safety and tolerability)

    Time frame: Up to week 4

Secondary outcomes

  1. Percentage of subjects with a serum uric level≤360μmol/L

    Time frame: At week1, 2, 3 and 4

  2. Percentage change from baseline in serum uric level .

    Time frame: At week1, 2, 3 and 4

  3. Actual change from baseline in serum uric level

    Time frame: At week1, 2, 3 and 4

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2019; primary completion for Jul 2020, 7 months later.

Of 24 phase 2 interventional studies under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2019
First posted
Nov 29, 2019
StartEst.
Dec 3, 2019
Primary completionEst.
Jul 30, 2020
CompletionEst.
Aug 30, 2020
Last update
Dec 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04180982
Responsible party
Sponsor
First posted
Nov 29, 2019
Start date
Dec 3, 2019 (estimated)
Primary completion
Jul 30, 2020 (estimated)
Completion
Aug 30, 2020 (estimated)
Last update
Dec 2, 2019

Study contacts

Liu Yi
Contact
hxyyhfb@163.com
028-85423237
Liu Yi
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion